

## LCA data dictionary

Column heading	Description
DIN	Drug Identification Number (DIN)/ Natural Product Number (NPN) assigned to each product by Health Canada.
CHEMICAL NAME	Chemical name for each drug.
DRUG NAME	Product name associated with a specific manufacturer's version of a drug.
MAN	Manufacturer code assigned by Health Canada. For more information, refer to the <a href="#">List of Manufacturer Codes</a> .
FULL/PARTIAL LCA BENEFIT	This column indicates whether a product is fully covered by PharmaCare: <b>F</b> – Full Benefit – fully covered by PharmaCare, subject to the Maximum Pricing Policy. <b>P</b> – Partial Benefit – coverage is limited according to LCA or RDP pricing policy. <b>P*</b> – Full benefit if Special Authority (SA) approval has been granted for an exemption from RDP rules.
PLAN B ONLY	Y – Benefit <b>for Plan B patients only</b> . These drugs are subject to LCA or RDP rules.
RDP	RDP – Subject to the rules of the Reference Drug Program (RDP). Claims for RDP drugs adjudicate according to the LCA program and up to a maximum daily cost determined by the cost of the reference drug comparator. REF – Reference drug for category. All claims for a REF drug adjudicate according to LCA program rules. Blank – Drug is not in the RDP.
SA	Y – Limited coverage drug that is covered only with Special Authority (SA) approval. Claims for SA drugs adjudicate to zero unless SA approval was entered in PharmaNet <b>before</b> the prescription is filled. Valid claims for an SA drug adjudicate according to LCA program rules.
PROV	Y – Listed on a provisional basis and may be removed from the PharmaCare formulary at the Minister's discretion. For details, refer to the <a href="#">Drug Price Regulation</a> .
PAN-CANADIAN	Y – Subject to the fixed prices set for select molecules by the pan-Canadian Pharmaceutical Alliance (pCPA). For a complete list of the pan-Canadian Select Molecules, refer to the <a href="#">pCPA web page</a> . For further details, refer to the <a href="#">March 1, 2018 PharmaCare Newsletter</a> .
TIERED PRICING CATEGORIES	Y – Subject to the price established in accordance with the <a href="#">pCPA Tiered Pricing Framework</a> for generic drugs.
MAX PRICE	Maximum price that PharmaCare will reimburse for the drug. <sup>1,2,3</sup>
LCA PRICE	Maximum amount PharmaCare will reimburse for a partial benefit in a particular LCA category. <sup>1,2</sup>

<sup>1</sup> When there is a price in both the Max Price and LCA Price column, claims adjudicate to the lower of the two prices.

<sup>2</sup> If a product is an RDP product, it will be adjudicated at the lesser of the Max Price, LCA Price or RDP Price.

<sup>3</sup> In some cases, the price entered in the LCA Price column may exceed that price entered in the MAX Price column.

## RDP data dictionary

Column heading	Description
<b>RDP CATEGORY</b>	A group of drugs, used to treat the same illness or condition, that are equally safe and effective. Within each category, fully covered (“reference”) drugs are not subject to a daily maximum; partially covered (“non-reference”) drugs are.
<b>DIN</b>	Drug Identification Number (DIN)/ Natural Product Number (NPN) assigned to each product by Health Canada.
<b>GENERIC NAME</b>	Chemical name for each drug.
<b>DRUG NAME</b>	Product name associated with a specific manufacturer's version of a drug.
<b>MAN</b>	Manufacturer code assigned by Health Canada. For more information, please see the <a href="#">List of Manufacturer Codes</a> .
<b>RDP</b>	The RDP price is determined by the cost of the reference drug. "Full (REF)" refers to the reference drug(s) in the category. "Partial (NONREF)" indicates that the drug will be reimbursed to a maximum of the price of the reference drug.

## Additional Resources

For current LCA and RDP data, refer to the [LCA and RDP Data Files](#) on the PharmaCare website.

For complete information on the LCA and RDP program and RDP, refer to the PharmaCare Policy Manual:

- for the LCA Program, see [Section 5.11](#)
- for the RDP, see [Section 5.12](#)